TrialBlood2007

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Jeffrey E Lancet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.